Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 5, 2022

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2030

Conditions
Prostate Cancer
Interventions
RADIATION

Image-guided Radiotherapy

de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Center, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER